Access

Business

Nature 446, 15 (1 March 2007) | doi:10.1038/446015a; Published online 28 February 2007

A merger too far?

Top

Bristol-Myers Squibb has been stoking its research productivity. Meredith Wadman investigates whether an acquisition would be the right prescription for the company.

Last month, the drug industry was abuzz with reports that Sanofi-Aventis was set to buy up Bristol-Myers Squibb. The move would make Paris-based Sanofi the world's second-largest drug maker, after Pfizer.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

ASCPT News

Clinical Pharmacology & Therapeutics News and Views

News and Views

Clinical Pharmacology & Therapeutics News and Views